Clinical Trial Update: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study update of the HDAC inhibitor quisinostat in previously treated Cutaneous T-Cell Lymphoma (Stage Ib-IVa) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides
• Sézary Syndrome

Drugs mentioned

• Quisinostat (quisinostat)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Lymphoma, T-Cell, Cutaneous | Phase 2 | Status: COMPLETED